Brian M Lin1, Wen-Qing Li2, Eunyoung Cho3, Gary C Curhan4, Abrar A Qureshi3. 1. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: brian_lin@meei.harvard.edu. 2. Department of Dermatology, Warren Alpert Medical School, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island. 3. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Warren Alpert Medical School, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island. 4. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Statins are among the most commonly used medications in the United States, and statin use is associated with increased risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). However, previous studies are limited by lack of adjustment for important confounders. OBJECTIVE: Examine the relation between statins and skin cancer risk in the Nurses' Health Study and Health Professionals Follow-up Study. METHODS: Cox proportional hazards regression was used to evaluate associations. RESULTS: During follow-up (2000-2010), we documented 10,201 BCC, 1393 SCC, and 333 melanoma cases. History of high cholesterol level was not associated with risk of BCC (pooled multivariable-adjusted hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.00-1.09), SCC (HR, 0.95; 95% CI, 0.85-1.06), or melanoma (HR, 0.87; 95% CI, 0.64-1.19). Statin use was not associated with risk of BCC (HR, 1.04; 95% CI, 0.99-1.09]), SCC (HR, 1.08; 95% CI, 0.94-1.24), or melanoma (HR, 1.04; 95% CI, 0.78-1.38). There was a trend toward higher BCC risk with longer duration of statin use in men (P trend = .003) but not in women (P trend = .86). LIMITATIONS: Lack of treatment data. CONCLUSION: History of high cholesterol level was not associated with skin cancer risk. Longer duration of statin use was associated with a trend toward higher BCC risk in men.
BACKGROUND: Statins are among the most commonly used medications in the United States, and statin use is associated with increased risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). However, previous studies are limited by lack of adjustment for important confounders. OBJECTIVE: Examine the relation between statins and skin cancer risk in the Nurses' Health Study and Health Professionals Follow-up Study. METHODS: Cox proportional hazards regression was used to evaluate associations. RESULTS: During follow-up (2000-2010), we documented 10,201 BCC, 1393 SCC, and 333 melanoma cases. History of high cholesterol level was not associated with risk of BCC (pooled multivariable-adjusted hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.00-1.09), SCC (HR, 0.95; 95% CI, 0.85-1.06), or melanoma (HR, 0.87; 95% CI, 0.64-1.19). Statin use was not associated with risk of BCC (HR, 1.04; 95% CI, 0.99-1.09]), SCC (HR, 1.08; 95% CI, 0.94-1.24), or melanoma (HR, 1.04; 95% CI, 0.78-1.38). There was a trend toward higher BCC risk with longer duration of statin use in men (P trend = .003) but not in women (P trend = .86). LIMITATIONS: Lack of treatment data. CONCLUSION: History of high cholesterol level was not associated with skin cancer risk. Longer duration of statin use was associated with a trend toward higher BCC risk in men.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: R M van Dam; Z Huang; E Giovannucci; E B Rimm; D J Hunter; G A Colditz; M J Stampfer; W C Willett Journal: Am J Clin Nutr Date: 2000-01 Impact factor: 7.045
Authors: Alan C Geller; Richard W Clapp; Arthur J Sober; Lou Gonsalves; Lloyd Mueller; Cindy L Christiansen; Waqas Shaikh; Donald R Miller Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Wen-Qing Li; Eunyoung Cho; Martin A Weinstock; Hasan Mashfiq; Abrar A Qureshi Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Richard Peto; Jonathan Emberson; Martin Landray; Colin Baigent; Rory Collins; Robert Clare; Robert Califf Journal: N Engl J Med Date: 2008-09-02 Impact factor: 91.245
Authors: Eric A Collisson; Celina Kleer; Mei Wu; Abhijit De; Sanjiv S Gambhir; Sofia D Merajver; Michael S Kolodney Journal: Mol Cancer Ther Date: 2003-10 Impact factor: 6.261
Authors: Ange Wang; Aaron K Aragaki; Jean Y Tang; Allison W Kurian; JoAnn E Manson; Rowan T Chlebowski; Michael Simon; Pinkal Desai; Sylvia Wassertheil-Smoller; Simin Liu; Stephen Kritchevsky; Heather A Wakelee; Marcia L Stefanick Journal: Br J Cancer Date: 2016-06-09 Impact factor: 7.640
Authors: Jonas A Adalsteinsson; Sonal Muzumdar; Reid Waldman; Chaoran Hu; Rong Wu; Désirée Ratner; Hao Feng; Jonathan Ungar; Jonathan I Silverberg; Gudridur H Olafsdottir; Arni Kjalar Kristjansson; Laufey Tryggvadottir; Jon Gunnlaugur Jonasson Journal: Arch Dermatol Res Date: 2021-03-27 Impact factor: 3.033
Authors: Elisabeth A George; Navya Baranwal; Jae H Kang; Abrar A Qureshi; Aaron M Drucker; Eunyoung Cho Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639